Q32 Bio Inc. (NASDAQ: QTTB) – a clinical-stage biotech focused on alopecia areata and autoimmune diseases – has seen its stock price skyrocket after positive Phase 2 trial results and is now moving to raise substantial capital. On July 13, Q32 announced 36-week topline data showing meaningful hair regrowth with its drug bempikibart in severe alopecia patients, sending shares up over 60% (opening at $18.31 vs. $11.21 prior close, with an intraday high of $22.50) (www.fiercebiotech.com). Following this surge, the company launched an underwritten public offering to sell ~$200 million in common stock (and pre-funded warrants to certain investors) (www.stocktitan.net). This report dives into Q32’s financial profile – dividend policy, leverage, valuation metrics, and key risks – to assess the implications of the offering and the road ahead.

Dividend Policy and Yield

Q32 Bio does not pay any dividends, as is typical for development-stage biotechs. The company has never declared a dividend and offers no dividend reinvestment program (ir.q32bio.com). Instead, all available capital is reinvested into R&D and clinical trials. Traditional income metrics like dividend yield, AFFO, or FFO – relevant for mature cash-generative firms – do not apply here. Q32 has reported net losses each year since inception and has no positive funds-from-operations to distribute (its earnings and cash flow are negative, reflecting heavy R&D spend) (www.mk.co.kr). Consequently, yield-focused investors should not expect near-term returns from dividends. Management’s focus is on capital appreciation via clinical success rather than shareholder payouts. In fact, analysts forecast Q32 will remain unprofitable through at least 2028 (projected EPS of –$1.83 in 2026, with losses continuing in 2027–28) (www.mk.co.kr). Until the company achieves a stable revenue stream (likely post-drug approval), return of capital is off the table – Q32’s value proposition lies in potential future product sales, not current income.

Financial Position and Leverage

Cash Runway: As of March 31, 2026, Q32 Bio had $50.8 million in cash and equivalents (ir.q32bio.com). Management has actively extended its funding runway through strategic deals. For example, in Q1 2026 the company completed a $10.5 million registered direct offering (RDO) to bolster working capital for its trials (ir.q32bio.com). Additionally, Q32 sold an early-stage asset (ADX-097) for $7 million and entered an ATM (at-the-market) equity program, with combined proceeds plus expected milestone payments projected to fund operations into the first half of 2028 (ir.q32bio.com). This cash runway projection was before the latest financing news; subsequent raises significantly improve the balance sheet. In late May, Q32 secured an additional $55 million via a private placement led by top-tier biotech investors (BVF Partners, RA Capital, OrbiMed, and Atlas Venture) (www.stocktitan.net). The company issued ~6.725 million shares at $8.00 each, plus 150,000 pre-funded warrants at the same effective price (www.stocktitan.net). Notably, this $8 pricing represented a 45% premium to the prior stock price – a vote of confidence by insiders (finance.sina.com.cn). The deal closed on May 28, 2026, bringing pro forma cash to roughly $100+ million (before Q2 burn), and Q32 agreed to file an SEC registration to allow resale of these shares/warrants (www.stocktitan.net).

Debt and Interest: Q32 Bio carries minimal debt relative to equity. It has a venture debt facility (originally up to $25 million with Silicon Valley Bank) that had about $9.7 million outstanding at 2025 year-end (ir.q32bio.com). This loan has been amended multiple times and matures on July 1, 2027 (ir.q32bio.com). Principal repayments have begun – $3.1 million was paid in 2025, leaving a current portion of $6.2 million due within 12 months (ir.q32bio.com). Interest expense on this debt was ~$1.1 million in 2024 (ir.q32bio.com), a cost largely offset by the company’s interest income on cash that year (and by a one-time $2.2 million gain from fair-value adjustment of merger-related liabilities) (ir.q32bio.com). In other words, interest coverage has not been a constraint – Q32’s cash reserves and interest income have comfortably covered loan interest so far. With the recent influx of equity capital, Q32 is well-positioned to service or even prepay its debt. The venture loan’s covenants (typical restrictions on liens, additional debt, etc.) have not impeded operations, and the company may opt to retire this debt as maturity nears if cash is ample (ir.q32bio.com) (ir.q32bio.com). Overall, leverage is low – total liabilities are modest and primarily consist of the venture loan and standard lease obligations (ir.q32bio.com). Q32’s clinical development is being funded mostly by equity rather than debt, which limits financial risk at the cost of dilution (as discussed below).

Coverage and Liquidity: With no positive EBITDA, traditional interest coverage ratios are not meaningful. More relevant is cash coverage of R&D needs. Q32’s proactive financing has ensured it can meet operating expenses and trial costs for the next ~2 years even without revenue. The company explicitly stated that existing cash (including an upfront from the ADX-097 deal and some ATM sales) would fund it into mid-2028 (ir.q32bio.com) – a timeline that likely assumes completion of Phase 3 trials. The new $55 million private placement extends that runway further, de-risking near-term liquidity. If the pending $200 million offering closes (discussed next), Q32 would add a very large cash cushion. In summary, liquidity is strong for an early-stage biotech, and default risk is minimal given the low debt and substantial cash on hand. Q32’s challenge is not servicing obligations but rather efficiently deploying this capital to achieve pivotal trial success before it needs any further funding.

Valuation and Recent Offering

Stock Surge on Data: Q32’s valuation is primarily driven by its drug pipeline prospects, since it has no product revenue. The recent Phase 2a data for bempikibart dramatically shifted market sentiment. Investors rewarded the positive readout by sending QTTB shares sharply higher – the stock opened ~63% above the prior close and reached $22.50 in trading on the news (www.fiercebiotech.com). By midday July 13, Q32’s market capitalization swelled to roughly $360 million (www.stocktitan.net). This market cap, for context, far exceeds the company’s tangible book value (~$90–100 million of post-financing cash plus remaining assets), implying that investors are pricing in significant future earnings from a successful alopecia therapy. In essence, Q32 now trades at 3–4× its cash holdings, reflecting optimism that bempikibart can eventually be monetized (ir.q32bio.com) (www.stocktitan.net). Traditional valuation multiples like P/E or even P/FFO are not applicable due to negative earnings and negative operating cash flow. Instead, biotech valuation is assessed by pipeline potential and comparative transactions. For example, an approved alopecia treatment can be a lucrative asset – Eli Lilly’s JAK inhibitor (baricitinib) is already on the market for alopecia areata, and a small biotech (Concert Pharmaceuticals) with a Phase 3 alopecia drug was acquired for around $0.5 billion in 2023. With Q32’s market cap now in the ~$300–400 million range, investors are effectively betting that bempikibart could achieve similar success if Phase 3 is positive.

$200 Million Equity Offering: Capitalizing on the share price strength, Q32 Bio announced an underwritten public offering of $200 million in new equity (plus a customary 30-day option for underwriters to buy an extra ~$30 million in shares) (www.stocktitan.net). The offering will be made from an already-effective $300 million shelf registration, enabling a quick execution (www.stocktitan.net). Importantly, this raise is all primary (new shares/warrants issued by the company), meaning it will substantially dilute existing shareholders. At the current ~$19–20 stock price, a $200 million issuance corresponds to roughly 10–11 million new shares (on top of ~18 million shares estimated outstanding after the recent private placement). In other words, share count could increase ~60%, though the final terms will depend on market pricing. The market’s immediate reaction to the offering news was muted – QTTB shares dipped about 6.6% to ~$19.96 (www.stocktitan.net). Such a modest pullback suggests that investors anticipated a financing and view it as necessary to fund Phase 3 and beyond. This reception contrasts with the positive reactions to Q32’s earlier, smaller raises. (Notably, a $10.5 M direct offering in Feb 2026 boosted the stock +9.7% the next day (www.stocktitan.net), and the $55 M private deal in May 2026 was viewed so favorably that QTTB soared ~60–80% on the news (finance.sina.com.cn) (www.stocktitan.net) – largely because that deal came at a premium price and brought renowned biotech funds on board.) By comparison, the new $200 M issue is an order of magnitude larger, likely at a slight discount, and will significantly enlarge the float. It’s therefore natural that some dilution-driven selling pressure emerged (www.stocktitan.net). Still, the fact that Q32’s stock is holding near ~$20 indicates that investors see long-term value outweighing dilution – essentially, the cash injection (if completed) could fully fund pivotal trials and increase the odds of ultimate drug approval, benefiting all shareholders in the long run.

Current Valuation Metrics: With the offering in progress, pro-forma cash could exceed $250–300 million (adding $200 M to the ~$80–100 M post-May balance). In that scenario, Q32’s enterprise value (EV) – market cap minus cash – would be on the order of $100 million or less, reflecting the value the market assigns to the pipeline itself. Another way to view valuation is price-to-book: prior to the new issuance, Q32’s P/B was around 3× (market cap ~$360 M vs. ~$120 M total equity post-May financing) (www.stocktitan.net) (www.stocktitan.net). If $200 M is added to equity, the P/B multiple would drop closer to 1.5–2× (assuming the share price holds), making the stock look more “reasonable” on a balance-sheet basis. Of course, for a biotech with no revenues, these metrics are secondary to clinical outlook. It’s worth noting that Wall Street analysts had set price targets in the mid-teens before the Phase 2 data – for instance, Mizuho initiated coverage at Outperform with a $14 target in May (finance.sina.com.cn). After the strong trial results, those targets may be revised upward. In sum, QTTB’s valuation has run up on excitement for bempikibart’s potential. The planned offering will dilute the stock but greatly strengthen Q32’s cash reserves, ideally bridging the company to pivotal trial completion. If bempikibart succeeds in Phase 3 and reaches market, the current ~$0.3–0.4 billion valuation could prove modest; if it fails, the valuation could contract toward cash levels. Thus, Q32’s investment thesis is binary, hinging on clinical outcomes rather than traditional financial ratios.

Pipeline Progress and Market Potential

At the heart of Q32’s story is bempikibart (ADX-914), its novel immune-regulating antibody for alopecia areata (AA). The drug targets the interleukin-7 receptor alpha (IL-7Rα), thereby blocking IL-7 and TSLP signaling to “re-balance” the immune system in autoimmune conditions (ir.q32bio.com). Alopecia areata – an autoimmune attack on hair follicles – has seen recent breakthroughs with JAK inhibitor pills, but Q32 is aiming to provide a more durable and targeted therapy (www.fiercebiotech.com) (www.prnewswire.com). The Phase 2a SIGNAL-AA trial (Part B) results unveiled on July 13 are encouraging. In 33 patients with severe or very severe alopecia, bempikibart achieved its primary efficacy endpoint with clinically meaningful hair regrowth (www.prnewswire.com) (www.prnewswire.com). Specifically, at Week 36: – 30.3% of patients reached a SALT-20 response (meaning they had ≤20% scalp hair loss, equating to at least 80% hair coverage) in the overall intent-to-treat population (www.fiercebiotech.com). – In a prespecified modified ITT analysis (excluding certain deviations), 40.0% of patients achieved SALT-20 regrowth (www.prnewswire.com). These are significant response rates in a refractory alopecia population. For additional context, 33.3% of patients achieved a ≥50% improvement (SALT-50 response), showing that one-third had at least half of their hair grow back (www.fiercebiotech.com).

Equally important, bempikibart showed a favorable safety profile. There were no treatment-related serious adverse events and no Grade 3/4 adverse events observed (www.fiercebiotech.com). The most common side effect was mild injection-site reactions in about 36% of patients, all of which resolved quickly (www.fiercebiotech.com). This safety/tolerability is comparable to or better than systemic JAK inhibitors, which can carry immunosuppressive risks. Q32’s management highlighted “early signs of durability in the off-drug period” – some patients maintained or continued to improve even after stopping bempikibart (www.fiercebiotech.com). Durability could be a key differentiator versus daily JAK pills, aligning with Q32’s thesis of targeting an upstream immune regulator for more lasting remission (www.prnewswire.com).

On the back of these results, Q32 Bio declared the dataset a “significant milestone” and is preparing for a registration-directed program (www.prnewswire.com). The company plans to initiate Phase 3 trials (or other pivotal studies) in H1 2027 (www.prnewswire.com) (www.prnewswire.com). The fresh capital from the $200 M raise would presumably fund these larger trials, which will enroll many more patients to confirm efficacy and safety. Market potential: If ultimately approved, bempikibart could address a sizeable unmet need – an estimated 700,000 people in the U.S. live with alopecia areata (ir.q32bio.com), many of whom are dissatisfied with or ineligible for current therapies. The existing JAK inhibitor treatments (like Lilly’s baricitinib, approved for AA in 2022) have shown ~30–40% of patients achieving significant hair regrowth in trials, but their effects may wane after discontinuation and they carry black-box safety warnings. Q32’s goal is to offer patients a targeted biologic with durable benefit (www.prnewswire.com). While it’s too early to know if bempikibart can unseat the incumbents, the Phase 2 data provide proof-of-concept that this novel mechanism has real activity in alopecia. Investors’ bullish reaction underscores that Q32 is now seen as a legitimate contender in the multi-billion-dollar alopecia treatment market.

It’s worth noting that Q32’s pipeline beyond alopecia is limited at this stage. The company’s other main asset (a complement inhibitor program, ADX-097) was out-licensed – Q32 sold it to Horizon Therapeutics to obtain non-dilutive funds (ir.q32bio.com). While this deal brought in cash (with potential milestones), it leaves Q32 essentially a one-product company for now. Management may explore bempikibart in other autoimmune diseases given the IL-7/TSLP pathway is implicated in conditions like autoimmune asthma or inflammatory disorders (ir.q32bio.com). But the immediate focus is on alopecia areata. Success in AA could unlock expansion opportunities, whereas failure would leave Q32 with a far less certain pipeline. Thus, from a pipeline perspective, Q32 is high-risk, high-reward – concentrated on bempikibart’s trajectory, with the recent data moving the odds in a favorable direction.

Risks, Red Flags, and Open Questions

Despite the optimistic developments, Q32 Bio carries significant risks and uncertainties:

– Clinical and Regulatory Risk: The positive Phase 2a results must be confirmed in larger trials. Risks remain that the Phase 3 trials could fail to meet endpoints or reveal safety issues not seen in the small Phase 2. Alopecia areata can be a variable disease – placebo and relapse rates might differ in a broader population. Moreover, regulatory approval isn’t guaranteed; the FDA will scrutinize durability of response and safety (especially given the chronic treatment setting). Any hiccup in trial execution or data outcomes would heavily impact QTTB’s valuation.

– Competition and Market Adoption: Competitive dynamics pose a risk. FDA-approved JAK inhibitors (Eli Lilly’s Olumiant and Pfizer’s Litfulo) are already on the market for alopecia areata, establishing a standard of care. By the time bempikibart could launch (likely 2028 or later), these oral drugs will be well-entrenched. Q32 will need to clearly demonstrate a meaningful advantage – e.g. better long-term remission or fewer side effects – to capture market share. Physicians might be cautious to adopt a new biologic over pills unless the differentiation is evident. Additionally, other biotechs are pursuing alternatives (such as broad immunomodulators or regenerative approaches), so Q32 must stay ahead. The company’s claim of greater durability vs. JAK inhibitors (www.fiercebiotech.com) will need validation in longer-term studies.

– Financing and Dilution: Q32’s strategy is highly capital-intensive. The company has repeatedly turned to equity financing to fund its R&D, which dilutes existing shareholders. While past raises were done at advantageous terms (even at premiums) (finance.sina.com.cn) (www.stocktitan.net), the sheer scale of the new $200 M offering is a dilution red flag. If the offering prices significantly below market or if demand is weak, current shareholders could see their ownership and per-share value erode. Even assuming the $200 M is raised, Q32 might still require additional financings before reaching profitability. Late-stage trials and a commercial launch would consume significant cash, potentially necessitating a partner or further offerings down the road. The risk of future dilution remains high, common for pre-revenue biotechs.

– Execution and Operational Risk: As a young company (Q32 was formed via a reverse merger in 2024), Q32 Bio faces execution challenges. Scaling up from a 33-patient trial to global Phase 3 trials is a major leap. The company will need to enroll hundreds of patients, manage clinical sites, and maintain quality and compliance – all areas where delays or setbacks can occur. Manufacturing a biologic drug at larger scale is another hurdle; any production glitches could slow development. Furthermore, key personnel risk is present – Q32’s team is relatively small (~24 employees as of mid-2026) (origin.rootz.global). Retaining talent and expertise (especially as the pipeline was refocused after the Homology merger) is critical. Any turnover in leadership or science roles (for example, if key scientists from the Homology side depart) could impact progress.

– Lack of Diversification: As noted, Q32 is essentially a single-asset company post-merger. This concentration increases risk. If bempikibart encounters problems (clinical failure, slow enrollment, unexpected adverse events, etc.), Q32 has no other independent clinical programs to fall back on. The successful sale of ADX-097 provided cash but also removed a potential backup asset. While management likely sold it to stay focused and extend runway, the downside is all eggs are now in one basket. Investors should be aware that QTTB’s fortunes hinge entirely on one mechanism of action – a classic “binary outcome” biotech scenario.

– Extended Timeline to Revenue: Even in a success case, Q32 Bio will not generate product revenue for several years. Bempikibart would need to complete Phase 3 trials (which won’t even start until 2027) (www.prnewswire.com), then secure regulatory approvals (likely ~2028), and then ramp up sales. Thus, the company is looking at 2028–2029 before any substantial revenue, and profitability would come even later. This long horizon entails opportunity cost and discounting risk – future cash flows are far-off and uncertain, which can limit near-term stock upside. It also means Q32 must carefully manage its cash to avoid running out before reaching the finish line. Management’s current projection of cash runway into 1H 2028 (ir.q32bio.com) assumes things go as planned; any trial extension or new initiative could compress that timeline.

– Macroeconomic and Market Risk: Broader conditions can affect Q32’s risk profile. Rising interest rates or risk-off sentiment can hurt biotech valuations and make fundraising harder (though Q32’s timely raise mitigates immediate need). Volatility in equity markets could impact the execution of the $200 M offering or its pricing. Also, changes in healthcare policy or reimbursement for alopecia treatments by 2028 could influence the eventual commercial opportunity. These are external factors largely out of Q32’s control but nonetheless important for investors to monitor.

In terms of red flags, one could point to the pattern of frequent fundraising – however, Q32 has so far navigated this adeptly by raising at opportune moments and with reputable partners. A more positive interpretation is that high-caliber biotech funds have repeatedly invested, signaling confidence. For instance, BVF, RA Capital, and others not only participated in May’s private placement but likely see long-term value in Q32 (www.stocktitan.net). Another potential concern was the legacy of the Homology Medicines merger (completed March 2024) – sometimes reverse mergers leave overhangs like legacy liabilities or misaligned shareholders. Q32 did inherit a contingent value right (CVR) liability tied to Homology’s assets (initially valued ~$55 M) (ir.q32bio.com), but that appears to have been written down as Homology’s programs were shelved (Q32 even recorded a gain from the CVR’s reduced fair value) (ir.q32bio.com). Thus, any red flag from the merger looks contained, and Q32 is effectively a clean slate focusing on its core drug. Still, it will be important to watch if former Homology shareholders flip their holdings (post-merger they owned a chunk of QTTB) or if there’s insider selling after big stock spikes – either could put pressure on the stock.

Open questions going forward include: – Will Q32 form a partnership or continue solo? Now that Phase 2 proof-of-concept is established, Q32 could attract a larger pharma partner for Phase 3 and commercialization. A partnership (or even acquisition) could provide non-dilutive funding and commercial infrastructure. On the other hand, Q32 might prefer to retain full ownership through Phase 3 and raise money via equity (as the current offering suggests). How the company balances independence vs. partnership is a key strategic question. – Can the $200 M offering be completed at favorable terms? Thus far, investor appetite seems strong, but markets can shift. The final pricing of this offering (and whether the full amount is raised) will impact how much dilution occurs and how much cash Q32 actually nets. Closing this financing is crucial for Q32 to execute its plans without financial strain. If the raise falters or has to be downsized, Q32’s development timeline might be jeopardized. – What will Phase 3 look like? The design of the next trial is an open question: What patient population, dosing regimen, and endpoints will Q32 pursue in Phase 3? Will they attempt a head-to-head vs. a JAK inhibitor to prove differentiation? Management indicated a “registration-directed program” by 1H 2027 (www.prnewswire.com), but details are pending. Investors will be eager for the Phase 3 protocol and regulatory feedback – these will clarify bempikibart’s path to approval. – How durable is bempikibart’s effect? The Phase 2 followed patients off treatment for only a short period. An open-label extension is ongoing (ir.q32bio.com), which should yield more data on how long responses last after stopping therapy. Durable remission could be a major selling point. An open question is whether patients will need continuous treatment or can go on/off intermittently. The answers will influence market adoption and dosing strategy. – Are there other indications to pursue? IL-7 and TSLP pathways are involved in other autoimmune diseases. Q32 might explore secondary indications for bempikibart (for instance, alopecia totalis/universalis, or conditions like vitiligo or atopic dermatitis where adaptive immune modulation could help). Thus far, Q32 has not announced additional trials beyond alopecia. Investors may question if the company will broaden its pipeline or remain a one-product play until after Phase 3. Any moves to in-license or develop new assets would also be something to watch (using some of that new capital to diversify could be prudent, albeit with the risk of distraction).

Conclusion and Outlook

Q32 Bio finds itself at a pivotal juncture. The company’s lead asset has delivered encouraging mid-stage results, sparking a dramatic rise in its stock price and enabling a bold capital raise. Financially, Q32 is transforming – from a cash-constrained microcap into a well-funded biotech with the resources to push a drug through pivotal trials. If the $200 million offering closes as planned, Q32 will have a war chest likely sufficient to carry bempikibart through Phase 3 and even initial regulatory filings, all while maintaining a debt-light balance sheet. This greatly reduces financial risk in the near term. The trade-off, however, is substantial dilution to shareholders, which places pressure on the company to execute and create value with the new capital.

Looking ahead, the upside scenario is compelling: with strong Phase 3 data, bempikibart could become a breakthrough treatment in alopecia areata, potentially capturing a significant patient segment that seeks safer or more durable alternatives to JAK inhibitors. In that scenario, Q32’s valuation could climb into the realm of other successful dermatology/immunology biotech acquisitions or partnerships (well into the hundreds of millions or more). The downside scenario is that the drug disappoints in later trials or faces unforeseen hurdles, in which case Q32’s stock could retrace drastically toward its cash value – a fate not uncommon for single-product biotechs that stumble.

At the moment, momentum is in Q32’s favor. The participation of top-tier institutional investors in the recent private financing (www.stocktitan.net) and the market’s relatively calm reaction to the large offering suggest a level of confidence that Q32 is on the right track. Analysts, who were initially targeting stock prices around $13–14 (finance.sina.com.cn), may need to revisit their models given the improved data and funding. Still, investors should remain cognizant that execution risk is high and the road to approval is long. Key milestones to watch in coming quarters include the final results from the ongoing open-label extension (to gauge durability), any partnership announcements, and the initiation details of the Phase 3 program. Each of these will further inform Q32’s probability of success.

In summary, QTTB’s recent surge and offering represent a dramatic inflection point: the company is transitioning from a speculative micro-cap to a late-clinical-stage contender with a well-defined opportunity. No dividend, high R&D spend, and recurring losses will remain the norm for the foreseeable future – but those are acceptable in exchange for the potential of a new blockbuster therapy. Q32 Bio now has to justify the faith that the market and its investors have placed in it. The $200 M cash infusion must be deployed effectively to answer the remaining questions about bempikibart. If the company can do so, QTTB’s journey from a sub-$5 stock to double-digits may be just the beginning of a longer growth story. Conversely, any falter in clinical outcomes could quickly deflate the hype. For now, Q32 has bought itself time and resources, emerging as a well-capitalized, single-focus biotech set to chase a big prize in alopecia areata. Investors should brace for continued volatility but also recognize that Q32’s risk/reward profile has evolved – with more cash in hand and one critical mission ahead, the company stands at a crossroads where execution will determine whether its current soaring trajectory can be sustained.

Sources:

– Q32 Bio Investor FAQ (Dividend policy) (ir.q32bio.com) – Q32 Bio Q1 2026 Results (cash balance, runway guidance, recent financing) (ir.q32bio.com) – Q32 Bio SEC 10-K 2025 (venture debt outstanding and maturity) (ir.q32bio.com) (ir.q32bio.com) – Q32 Bio SEC 10-K 2025 (interest expense and income, financing history) (ir.q32bio.com) (ir.q32bio.com) – Q32 Bio Press Release May 27, 2026 (Private placement $55 M at $8/share, investors) (www.stocktitan.net) (www.stocktitan.net) – Sina Finance (Chinese) May 28, 2026 – institutional financing at premium and stock +64% to $11.64 (finance.sina.com.cn) (finance.sina.com.cn) – FierceBiotech Jul 13, 2026 – Phase 2 results summary and stock +60% surge (open $18.31, high $22.50) (www.fiercebiotech.com) – PR Newswire Jul 13, 2026 – Topline results PR (efficacy and safety data, Phase 3 plans) (www.prnewswire.com) (www.fiercebiotech.com) (www.prnewswire.com) – StockTitan News Jul 13, 2026 – Offering announcement (commenced $200 M underwritten offering, shelf details) (www.stocktitan.net) (www.stocktitan.net) – StockTitan Analysis Jul 13, 2026 – Market reaction to offering (–6.6%, ~$362 M market cap post-news) (www.stocktitan.net) (www.stocktitan.net) – StockTitan Analysis Feb 17, 2026 – Prior $10.5 M offering (+9.7% stock reaction) (www.stocktitan.net) – Maeil Business News (Korean) May 28, 2026 – Loss projections through 2028 (EPS –$1.83 in 2026, continuing losses) (www.mk.co.kr) – Q32 Bio CEO statement (PR) on trial results significance and strategy (www.prnewswire.com).

For informational purposes only; not investment advice.